Chronic hepatitis B (CHB) has become a treatable and controllable disease. The current nucleos(t)ide analogue (NUC) and pegylated interferon therapies effectively help slow disease progression and reduce the risk of cirrhosis, hepatocellular carcinoma (HCC), and CHB-associated mortality. Long-term viral suppression is easily achievable by NUC therapy, with limited adverse reactions. However, several unmet requirements still exist, including safety and risk-stratified HCC surveillance among patients who received long-term NUC therapy. Criteria for determining which patients should receive finite-duration NUC therapy and which should receive combination therapy with both NUC and pegylated interferon remain unsettled. The management of hepatitis B virus (HBV) e antigen-positive viremic patients with normal liver function and the incorporation of new biomarkers to help manage CHB require further exploration. To achieve functional cure (ie, HBV surface antigen seroclearance) and complete cure (ie, eradication of covalently closed circular DNA) of CHB, several challenges in basic research must be addressed, including the development of an efficient cell culture system and animal models for HBV investigation, development of treatment to eradicate covalently closed circular HBV DNA, and development of immunotherapy for CHB. This brief review focuses on unmet needs in both clinical and basic HBV research.
Chronic hepatitis B virus (HBV) infection is a global health problem, affecting >240 million patients worldwide and causing chronic hepatitis, liver cirrhosis, and hepatocellular carcinoma (HCC). The natural history of chronic hepatitis B (CHB) has been extensively studied, and effective vaccination successfully prevents the transmission of and new infection with HBV [1] . After the introduction of antiviral therapy, including 6 nucleos(t) ide analogues (NUCs; lamivudine, adefovir dipivoxil, entecavir, telbivudine, tenofovir disoproxil fumarate [TDF] , and tenofovir alafenamide [TAF] ) and 2 immunomodulators (conventional and pegylated interferons), CHB has become a treatable and controllable disease. Antiviral therapy can help normalize liver function, inhibit viral replication, clear viremia, ameliorate liver inflammation and fibrosis, and even achieve functional cure of hepatitis B (defined as HBV surface antigen [HBsAg] seroclearance), and it can ultimately reduce the risk of progression to cirrhosis, hepatic decompensation, HCC, liver-related death, and all-cause mortality [2] . Despite these achievable goals, several issues crucial to the management of CHB remain and need further consideration, including the effects of long-term indefinite NUC therapy, the risk of viral relapse after NUC discontinuation, the availability of new therapeutic options such as combination therapy, the management of patients in the HBV e antigen (HBeAg)-positive phase of chronic HBV infection (a phase formerly known as the immunologic tolerance phase) [3] , and the development of new biomarkers to better stratify disease status and help in the management of CHB.
Unlike chronic hepatitis C, which has a very high cure rate owing to the use of direct-acting antiviral agents, achievement of complete cure for CHB (defined as functional cure with eradication of covalently closed circular DNA [cccDNA] ) is still unachievable [4] . Efforts are needed to develop an efficient cell culture system and animal models for HBV investigation, to develop therapies to reduce the cccDNA load, and to elucidate the immunopathogenesis of HBV and develop new immunotherapeutic regimens. In this brief review, the unmet needs in clinical and basic HBV research will be addressed [ Table 1 ].
bone-associated adverse events [7] . Although a recent study suggests that NUC treatment does not increase the risk of renal-and bone-associated adverse events, nucleotide analogs may increase the risk of hip fracture, compared with nucleoside analogs [8] . Therefore, TAF, another prodrug of tenofovir but with a better safety profile, has been approved for treatment of CHB. Among patients in the HBeAg-positive phase of chronic HBV infection, TAF was noninferior to TDF in efficacy and had improved short-term bone and renal safety profiles [9] . However, the long-term safety profile of TAF needs to be monitored. The compliance of patients with long-term NUC therapy is another concern, because viral breakthrough or genotypic resistance may occur if compliance is poor [10] . In patients with persistent viral suppression, whether a reduced frequency of NUC therapy (e.g., administration every other day) may still control the virus warrants further investigation.
On the other hand, HCC still occurs in patients with cirrhosis during long-term NUC therapy, even after decades of viral suppression [11] ; therefore, it is crucial to identify the risk predictors of HCC development in these patients with profound viral suppression. Old age, male sex, HBeAg positivity, baseline AFP level of ≥7 ng/mL, and virologic response during treatment are predictors for the risk of HCC [6] . In addition, a model revealed that an end-stage liver disease score of >12 and diabetes mellitus are determinants for HCC in patients with cirrhosis during NUC therapy [12] . Active HCC surveillance is another important issue, to ensure that medical resources are properly reallocated and that unnecessary medical expenditures are reduced. The first thing is to identify patients who require HCC surveillance. Because the majority of patients achieve sustained viral suppression and a normalized alanine aminotransferase level during long-term NUC therapy, the additional role of HBsAg, fibrosis biomarkers (e.g., Mac-2 binding protein glycosylation isomer), and tumor markers (e.g., α-fetoprotein, α-fetoprotein L3, and prothrombin induced by vitamin K absence II) in predicting the HCC risk awaits further investigation. Since NUC therapy cannot eliminate the HBV genome after it has been integrated into the host chromosome, examination of whether earlier initiation of NUC therapy can prevent this oncogenic integration before irreversible liver damage takes place is warranted [13] .
At the time of writing, there are several risk scores for predicting HCC development in patients with CHB, including the CU-HCC score, the HCC nomogram, the GAG-HCC score, the REACH-B score, and the LSM-HCC score [14] . These scores incorporate risk factors for HCC, such as age, male sex, albumin level, HBV DNA level, HBeAg positivity, presence of the basal core promoter mutation, and liver stiffness. The clinical usefulness of these risk scores is limited because most were derived from treatment-naive Asian patients without cirrhosis at baseline. Since these scores may not be applicable to white patients with CHB, the PAGE-B score, derived from European patients receiving antiviral therapy, has been developed [15] . In clinical practice, determination of how to incorporate these risk scores and tailored HCC surveillance into the management of antiviral therapy recipients with CHB is urgently required.
In summary, the long-term efficacy and safety of antiviral therapy should be continuously monitored. HCC surveillance is still required, and risk predictors and risk scores for HCC should be incorporated into clinical practice.
NUC Therapy Delivered for a Finite Duration
Practice guidelines from Europe and the United States recommend that NUC therapy should continue until HBsAg loss, at least in HBeAg-negative patients with CHB [3, 16] . However, finite-duration NUC therapy has been practiced in resource-limited regions, especially in Asia. According to the recent European Association for the Study of the Liver (EASL) guideline, NUC treatment may be discontinued in HBeAgpositive noncirrhotic patients who achieve HBeAg seroconversion with undetectable HBV DNA for at least 12 months or in HBeAg-negative noncirrhotic patients with persistent virologic remission for ≥3 years [3] . The advantages of NUC discontinuation are a finite treatment duration, with improved adherence, reduced costs, and minimization of renal and bone toxicity. The disadvantages are the risk of reactivation of suppressed disease, resulting in an unpredictable worsening of disease and possible development of fulminant hepatitis and acute-on-chronic liver failure, even after sustained viral suppression by consolidation therapy for several years. Viral relapse after treatment cessation is common, and up to 70% of patients experience virologic relapse (defined as an HBV DNA level of >2000 IU/mL), while up to 50% of patients experience clinical relapse (defined as virologic relapse plus an alanine aminotransferase level of >2 times the upper limit of normal) [17] . On the other hand, from a recent meta-analysis, long-term virologic remission may still be achieved, and even 2% of patients experienced HBsAg loss after therapy discontinuation [18] .
It is therefore important to identify predictors for relapse after therapy cessation or posttherapy remission, to guide cessation of NUC therapy for optimal candidates. Serum HBsAg or HBV core-related antigen (HBcrAg) levels have been proposed to guide physicians in the cessation of NUC therapy [19, 20] because, in general, the risk of relapse decreases as the HBsAg or HBcrAg level decreases (described in more detail later). In patients with an end-of-therapy HBsAg level of <100 IU/mL, the sustained virologic response 12 months after therapy cessation was 46% [19] , indicating that finite-duration NUC therapy is still an option for select candidates. Prolonged viral suppression during treatment is expected to offer higher chances of viral remission after treatment cessation [18] . However, the optimal consolidation duration is still an open question [21] .
The timing for retreatment is another unsettled issue. Some HBeAg-negative patients develop early transient beneficial flares that can lead to long-lasting remission and even spontaneous HBsAg clearance [22] . On the other hand, fulminant hepatitis flare with liver decompensation leading to liver transplantation or mortality is not rare. Close monitoring after treatment cessation is thus very important. In summary, the optimal timing for NUC cessation and predictors for long-term remission remain unclear and await for further investigation.
Role of Combination Therapy With NUCs and Interferon
NUCs or pegylated interferon are current standards of care for treating CHB. NUCs can efficiently suppress HBV replication through viral polymerase inhibition; however, the reduction in levels of viral antigens (e.g., HBeAg and HBsAg) is limited because NUCs do not target cccDNA. The advantages of NUC therapy include oral administration, good tolerability, broad spectrum of indications, and high virologic responses, whereas the long-term safety profile, risk of drug resistance, and prolonged therapeutic duration are major concerns [3] . On the other hand, pegylated interferon therapy has both direct antiviral and immunomodulatory effects. Interferon suppresses HBV transcription from cccDNA, and therefore the reduction in the HBsAg level is greater than observed with NUCs. Finite duration and moderate durability after therapy cessation are the advantages of interferon therapy; however, the poor tolerability and high variability of responses has limited its clinical use [3] . Pegylated interferon and NUCs have different effects in restoring the impaired innate and adaptive immune responses [23] . Pegylated interferon alfa increases natural killer cell counts, with upregulation of tumor necrosis factor-related apoptosis-inducing ligand and interferon γ (IFN-γ) production [24] . In addition, HBV-specific CD8 + T-cell functions can be restored after long-term NUC therapy [25] . Combination therapy with NUCs and pegylated interferon increases the chance of curing CHB through their synergistic antiviral activity and immunomodulatory effects.
There are several strategies for combination therapy, including the simultaneous strategy (ie, concurrent use of NUCs and pegylated interferon), the add-on strategy (ie, NUC therapy with sequential addition of pegylated interferon), and the switch strategy (ie, long-term NUC or pegylated interferon therapy with a subsequent switch to pegylated interferon or NUCs, respectively, with or without a short period of overlap of both agents) [23] . Simultaneous therapy with pegylated interferon and TDF had significantly greater efficacy in reducing HBsAg, compared with TDF or pegylated interferon monotherapy [26] . Regarding the add-on strategy, addition of pegylated interferon to ETV therapy from week 24 to week 48 in the ARES study led to higher rates of virologic response during treatment and sustained virologic response (SVR) after treatment, compared with ETV monotherapy, but a pegylated interferon monotherapy arm was missing [27] . Late addition of pegylated interferon therapy may facilitate the discontinuation of NUC therapy. Finally, in patients receiving long-term NUC therapy with suboptimal responses, the switch to pegylated interferon helped with HBeAg seroconversion and HBsAg loss as demonstrated by the OSST trial [28] . However, data on the long-term effects after discontinuation of switch therapy are still lacking. In addition, heterogeneous patient populations and therapeutic regimens make the demonstration of a consistent benefit of combination therapy difficult. Accordingly, the EASL 2017 guidelines do not recommend de novo combination of 2 NUCs or a NUC plus pegylated interferon. Pegylated interferon add-on or switch strategies are also not recommended for patients with CHB and long-term virologic suppression. Nevertheless, an add-on or switch strategy may be considered for treatment-compliant patients with incomplete viral suppression during long-term NUC therapy [3] .
In summary, add-on or switch strategy of combination therapy with NUC plus pegylated interferon might have some benefits in highly specific patients. Many unresolved issues need to be investigated, such as the optimal regimen, patient selection, timing, and the duration of the combination strategy.
Treatment of Patients in the HBeAg-Positive Phase of Chronic HBV

Infection
The HBeAg-positive phase of chronic HBV infection is characterized by HBeAg positivity with high viral replication activity but low or minimal liver damage [3] . This phase is usually asymptomatic, with minimal or no liver fibrosis detected by histologic analysis [29] . Most of the viral population present during this phase is wild-type virus with an extremely low evolution rate, suggestive of low immunologic selection pressure from the host. However, in contrast to the tolerance of T cells to viral replication, one recent study suggests that young patients with CHB have more HBV-specific T cells with the ability to proliferate and produce cytokines than adult patients with CHB [30] . This challenges the notion of whether treatment for patients in this phase is needed. Therefore, the "HBeAg-positive phase of chronic HBV infection, " rather than the "immunologic tolerance phase, " might be a better description of this phase.
The liver disease progression is negligible during the HBeAgpositive phase. The rate of HBeAg seroconversion among patients in this phase who are receiving NUC therapy (ie, 1 of year of lamivudine treatment or 4 years of TDF treatment) is <5%, which is much lower than that for patients in the immunologic clearance phase. The low HBeAg seroconversion rate is also true for pegylated interferon therapy in this scenario [29] . Considering the limited disease progression and poor response rate, antiviral therapy may not be indicated for patients in the HBeAg-positive phase. However, the management of patients in this phase who are >40 years old is still challenging because older age, high viral load, and HBeAg positivity are associated with a higher risk of cirrhosis and HCC. According to the updated EASL guideline, patients in the HBeAg-positive phase may be treated if they are older than 30 years, regardless of the severity of liver histologic findings; however, the recommendation level is weak [3] . Whether prolonged antiviral therapy with persistent viral suppression has a beneficial effect in this special population remains to be explored.
New Biomarkers in the Optimal Management of CHB
With recent advances in molecular investigations, several biomarkers associated with the natural history of chronic HBV infection and the efficacy of antiviral therapy have been identified [31] . The HBsAg level is a well-established biomarker that reflects the active transcription of cccDNA or translation of messenger RNA. In treatment-naive patients, the HBsAg titer correlates with the HBV DNA level [32] , predicts inactive HBV carrier status and HBsAg loss after HBeAg seroconversion, and stratifies the risk of disease progression, hepatitis flare, cirrhosis, and HCC in patients with a low viral load [33] . In addition, quantitation of HBsAg during treatment is also useful for predicting the response to pegylated interferon therapy [33] . Several new roles for HBsAg quantitation have been explored. The maternal peripartum HBsAg level helps predict the risk of mother-to-infant HBV transmission [34] , and the end-of-therapy HBsAg level helps predict the risk of relapse after treatment cessation or sustained remission [19] . Because HBsAg expression can be derived from both the envelope gene of cccDNA and the integrated HBV genome, the HBsAg level is not a perfect biomarker for cccDNA level, especially in the HBeAgnegative phase of chronic HBV infection. New biomarkers that exclusively reflect the quantitative cccDNA level are still under exploration.
HBcrAg is composed of HBV core antigen (HBcAg), HBeAg, and a 22-kDa precore protein expressed by the precore/core gene [31] . Unlike the HBsAg level, the HBcrAg level is not derived from analysis of the integrated viral sequences and therefore yields information in addition to that provided by the HBsAg level. Previous reports suggest that the HBcrAg level closely correlates with intrahepatic cccDNA level. Baseline HBcrAg level predicts reactivation during immunosuppressive therapy [35] . HBcrAg level is a predictor of spontaneous HBeAg seroconversion [36] and is also associated with the risk of HCC in patients with CHB [37] . The end-of-therapy HBcrAg level, in combination with the HBsAg level, helps predict the risk of relapse after treatment cessation [20] . Most of these studies were performed in Japan, and further validation in other areas are needed.
Antibody to HBcAg (anti-HBc) is the first antibody to appear after HBV infection and correlates with the host immune response against HBV. A recent study suggested that the baseline anti-HBc level helps predict HBeAg seroconversion during pegylated interferon or NUC therapy [38] . However, further validation studies are lacking.
Serum HBV RNA is recently recognized as a potential biomarker in the management of CHB. The detailed characterization of these circulating RNAs is ongoing, a recent study suggested that HBV RNA is the encapsidated and enveloped virion containing pregenomic RNA (pgRNA), rather than the relaxed circular DNA genome, and reflects the active transcription of cccDNA in the liver [39] . Even during NUC therapy with undetectable HBV DNA in serum, the HBV pgRNA virions may still be detectable. Serum HBV RNA is an early predictor of HBeAg seroconversion during NUC therapy [40] . Undetectability of serum HBV RNA during treatment may serve as a predictive biomarker to guide the safe discontinuation of NUC therapy [39] . The standardization of the HBV RNA detection procedure is needed.
A summary of new biomarkers is listed in Table 2 . With so many serologic and virologic biomarkers in hand, how to integrate these biomarkers to better manage patients with CHB is an unmet need. More studies are necessary to confirm the clinical significance of these biomarkers.
UNMET NEEDS IN BASIC RESEARCH
Efficient Cell Culture System and Animal Model
The first unmet need in basic research involves efficient cell culture systems and animal models to study the authentic HBV life cycle and the immunopathogenesis of HBV infection and to develop antiviral therapy. Primary human hepatocytes, human hepatoma Huh7 and HepG2 cells lines, and HepaRG cells are limited in their ability to mimic the natural infection of HBV, including their short culture longevity and limited susceptibility to HBV infection [4] . After the discovery of sodium taurocholate cotransporting polypeptide (NTCP) as an HBV/HDV receptor, the NTCP-overexpressing HepG2 cell line helped basic research on HBV entry and drug development. However, this model is still far from ideal for studying the viral propagation and viral-host interactions. Regarding animal model system, chimpanzees are the natural host of HBV, but further research had been restricted. Tupaia belangeri (treeshews) are permissive for HBV infection but are limited by their availability and applicability. Woodchucks and Peking ducks are alternative surrogate models, but their disease pathogenesis differs from that of humans [41] . Genetically altered mouse models are convenient for studying a certain part of the authentic life cycle. For example, adenoviral as well as adeno-associated viral vectors have been used to transfer HBV genomes into the mouse liver and initiate HBV replication, with persistence for a few months with competent immunity, but cccDNA could not be studied [41] . On the other hand, immunodeficient human liver chimeric mice are helpful in the study of HBV infection and formation of cccDNA, but they are not suitable for investigating immunopathogenesis. NTCP-expressing animal models are under active evaluation [41] .
In summary, at present there is no single perfect in vitro or in vivo model for HBV research. The current models are specific to a given part of the HBV life cycle, and new models await further investigations.
Eradication of HBV cccDNA
HBV cccDNA is the template for the transcription of HBV RNAs and the production of infectious virions, which contain a partially double-stranded relaxed circular DNA (rcDNA).
cccDNA resides in the nucleus of hepatocytes in episomal form and drives the production of viral antigens (e.g., HBeAg and HBsAg). Currently available antiviral therapy cannot cure HBV infection because they target the reverse transcription step in the life cycle and do not affect the cccDNA transcription template [42] . To control cccDNA, several key steps should be targeted: capsid disassembly, inhibition of rcDNA entry into the nucleus, inhibition of conversion of rcDNA to cccDNA, physical elimination of cccDNA, inhibition of cccDNA transcription (epigenetic control), and inhibition of viral or cellular factors contributing to cccDNA stability/formation [4] . There are only limited experimental models available to study these steps and no consensus protocols for quantification, making biologic research of cccDNA a big challenge.
Eradication of cccDNA is an important research topic. Two structurally related disubstituted sulfonamide compounds interfere with rcDNA conversion into cccDNA, blocking the formation of cccDNA [43] . After cccDNA formation, interleukin 6 or IFN-α may target the cccDNA transcription machinery (e.g., transcription factor or chromatin-modifying enzymes) and may subsequently reduce the production of viral antigens and virions, which can lead to functional cure only [44] .
Purging cccDNA from infected hepatocytes leads to complete cure of HBV infection. Certain cytokines (e.g., IFNs and tumor necrosis factor) and HBV-specific T cells may eliminate HBV cccDNA by both noncytolytic and cytolytic mechanisms [44] . In addition to the potential immunotherapy-induced clearance of cccDNA, another approach involves the specific degradation of cccDNA. IFN-α and lymphotoxin-β receptor activation upregulated APOBEC3A and APOBEC3B cytidine deaminases and resulted in cccDNA deamination and degradation [45] . Another approach involves use of DNA cleaving enzymes (as genomic editing tools), including zinc-finger nuclease, TAL effector nucleases, and CRISPR-associated protein 9 systems, specifically target cccDNA [46] . In summary, efforts are needed to standardize the quantification of cccDNA, develop model systems, and verify new therapeutic agents in preclinical studies.
Immunotherapy for Chronic Hepatitis B
The innate and adaptive immune responses are impaired during chronic HBV infection [47] . Specifically, HBV is a weak inducer and active repressor of innate proinflammatory cytokines (e.g., IFN-γ) in hepatocytes. In addition, natural killer cells have defective noncytolytic antiviral activity and even regulate the antiviral T-cell response by deleting HBV-specific T cells [48] . Regarding the defective adaptive immunity in patients with CHB, the exhaustion and dysfunction of HBV-specific T-cell immunity may be caused by the high serum level of HBsAg and HBeAg and the tolerizing microenvironment of liver [49] . Multiple coinhibitory molecules (e.g., PD-1, CTLA4, LAG-3, CD160, TIM-3, and 2B4) are upregulated in HBV-specific T cells [50] . A detailed characterization of the extent of immunologic defects and virologic data in a heterogeneous population of patients with CHB is needed to tailor individualized immunotherapeutic strategies. Several immunotherapeutic agents have been developed in preclinical and early phase clinical trials. Toll-like receptor 7 agonist (e.g., GS-9620), a pattern-recognition receptor whose activation results in innate and adaptive immune stimulation, may induce an IFN response in vivo, but it failed to suppress HBV DNA or HBsAg levels in patients who were treatment naive or experiencing virologic suppression in a phase 1b trial [51] .
Another promising strategy for clearing HBsAg is via cytotoxic T cell (CTL)-induced immunotherapy. An ideal immunotherapy should combine profound viral suppression, to prevent uninfected hepatocytes against HBV infection (by current potent NUC therapy), and restoration of the HBV-specific CTL response, to clear the infected hepatocytes [52] . Therapeutic vaccines might enhance the HBV-specific CTL responses [49] , but 2 recent studies using therapeutic vaccines failed to prevent relapse after discontinuation of NUCs therapy [53] and failed to effectively clear HBsAg [54] .
In summary, a detailed characterization of the immunologic defects in patients with CHB is needed. The ideal immunotherapy should restore the defective innate and adaptive immune response to HBV. However, recent clinical trials with Toll-like receptor agonists or therapeutic vaccines failed, and further investigations are needed.
CONCLUSIONS
With an effective vaccine and antiviral therapy, CHB is a controllable disease; however, the rate of functional cure of CHB (<10%) is still far from satisfactory. Although long-term oral antiviral therapy is well tolerated with few adverse effects, there are still many unmet clinical needs in terms of how to treat this disease more efficiently with better efficacy. In addition, further basic research is need to better characterize the molecular biology and immunopathogenesis of CHB and to develop more-effective therapies to eradicate HBV and achieve functional and even complete cure. More efforts are required to conquer these unmet needs and achieve the WHO's global goal of a 65% reduction in mortality due to CHB by 2030. 
